168 related articles for article (PubMed ID: 32434577)
1. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
[TBL] [Abstract][Full Text] [Related]
2. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
4. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
5. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
6. Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.
Mander AP; Wason JM; Sweeting MJ; Thompson SG
Pharm Stat; 2012; 11(2):91-6. PubMed ID: 22232071
[TBL] [Abstract][Full Text] [Related]
7. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
8. Optimal multistage designs for randomised clinical trials with continuous outcomes.
Wason JM; Mander AP; Thompson SG
Stat Med; 2012 Feb; 31(4):301-12. PubMed ID: 22139822
[TBL] [Abstract][Full Text] [Related]
9. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
10. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
11. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
12. Spatial Two-stage Designs for Phase II Clinical Trials.
Kim S; Wong WK
Comput Stat Data Anal; 2022 May; 169():. PubMed ID: 35058669
[TBL] [Abstract][Full Text] [Related]
13. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
14. An optimal three-stage design for phase II clinical trials.
Ensign LG; Gehan EA; Kamen DS; Thall PF
Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
[TBL] [Abstract][Full Text] [Related]
15. Optimal designs for phase II clinical trials with heterogeneous patient populations.
Liu L; Cao S; Jung SH
J Biopharm Stat; 2023 Jan; 33(1):1-14. PubMed ID: 35793231
[TBL] [Abstract][Full Text] [Related]
16. Optimal three-stage designs for phase II cancer clinical trials.
Chen TT
Stat Med; 1997 Dec; 16(23):2701-11. PubMed ID: 9421870
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
18. Optimal flexible designs in phase II clinical trials.
Chen TT; Ng TH
Stat Med; 1998 Oct; 17(20):2301-12. PubMed ID: 9819829
[TBL] [Abstract][Full Text] [Related]
19. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
Wu Y; Shih WJ
Stat Med; 2008 Dec; 27(29):6190-208. PubMed ID: 18800338
[TBL] [Abstract][Full Text] [Related]
20. A modification of Simon's optimal design for phase II trials when the criterion is median sample size.
Hanfelt JJ; Slack RS; Gehan EA
Control Clin Trials; 1999 Dec; 20(6):555-66. PubMed ID: 10588296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
